Français
ItalianoBond AbbVie 2.15% ( US00287YBG35 ) in USD
| Issuer | AbbVie | ||||||||||||||||||||||||||||||||||||||||||||
| Market price | 100 % ⇌ | ||||||||||||||||||||||||||||||||||||||||||||
| Country |  United States
|
||||||||||||||||||||||||||||||||||||||||||||
| ISIN code |
 US00287YBG35 ( in USD )
|
||||||||||||||||||||||||||||||||||||||||||||
| Interest rate | 2.15% per year ( payment 2 times a year) | ||||||||||||||||||||||||||||||||||||||||||||
| Maturity | 11/18/2021 - Bond has expired | ||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||
| Minimal amount | 2 000 USD | ||||||||||||||||||||||||||||||||||||||||||||
| Total amount | 1 750 000 000 USD | ||||||||||||||||||||||||||||||||||||||||||||
| Cusip | 00287YBG3 | ||||||||||||||||||||||||||||||||||||||||||||
| Standard & Poor's ( S&P ) rating | BBB+ ( Lower medium grade - Investment-grade ) | ||||||||||||||||||||||||||||||||||||||||||||
| Moody's rating | Baa2 ( Lower medium grade - Investment-grade ) | ||||||||||||||||||||||||||||||||||||||||||||
| Detailed description |
AbbVie is a research-based biopharmaceutical company focused on developing and marketing innovative therapies in several key therapeutic areas including immunology, oncology, neuroscience, and ophthalmology. The Bond issued by AbbVie ( United States ) , in USD, with the ISIN code US00287YBG35, pays a coupon of 2.15% per year. The coupons are paid 2 times per year and the Bond maturity is 11/18/2021 The Bond issued by AbbVie ( United States ) , in USD, with the ISIN code US00287YBG35, was rated Baa2 ( Lower medium grade - Investment-grade ) by Moody's credit rating agency. The Bond issued by AbbVie ( United States ) , in USD, with the ISIN code US00287YBG35, was rated BBB+ ( Lower medium grade - Investment-grade ) by Standard & Poor's ( S&P ) credit rating agency. |
||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||
